Clinical trials
Atrophy clinical trials
Below are recruiting atrophy clinical trials, each written for real people, not researchers. We’re tracking 272 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06868628RecruitingPhase 2
Nasal spray for multiple system atrophy (MSA) study
This trial tests a nasal spray called Foralumab for people with multiple system atrophy (MSA). The goal is to see if the spray can help reduce symptoms or slow the disease. It is for people who are otherwise healthy enough to safely participate.
Boston, MassachusettsAges 30–85 - NCT06900374Recruiting
Radiofrequency treatment for vaginal dryness in breast cancer patients
This trial tests if a gentle radiofrequency treatment can help breast cancer patients with vaginal dryness that hasn't improved with standard moisturizers. It aims to improve comfort and quality of life.
LilleAges 40 years+ - NCT06920134Recruiting
Spinal cord stimulation for blood pressure in Parkinson's disease
This trial tests if electrical stimulation of the spinal cord can help manage blood pressure drops (orthostatic hypotension) in people with Parkinson's and related conditions. It might make daily activities like standing and walking easier.
Lausanne, Canton of VaudAges 18–90 - NCT06971094RecruitingPhase 3
Gene therapy for type 2 spinal muscular atrophy
This trial tests a new gene therapy called GC101 given as a one-time injection into the spinal fluid for people with type 2 spinal muscular atrophy (SMA). It may help improve motor function.
BeijingAges 2–12 - NCT06974253Recruiting
Guided Implant Placement for Full Upper Jaw
This study tests a technology that uses a computer-guided system (dynamic navigation) to place multiple implants in the upper jaw of people who have no teeth left. It aims to improve placement accuracy and make the surgery safer.
Ho Chi Minh CityAges 18 years+ - NCT07070999RecruitingPhase 1/Phase 2
Gene therapy GB221 for infants with SMA type 1
This trial tests a new gene therapy called GB221 for infants with SMA type 1, a rare muscle-weakening disease. It aims to see if this treatment can improve muscle strength and development, and it is for babies who have not had prior gene therapy.
Porto Alegre, Rio Grande do SulAges 2 weeks–1 year - NCT07158775RecruitingPhase 1/Phase 2
BS01 gene therapy for dry age-related macular degeneration
This trial tests a new gene therapy, BS01, given as an eye injection. It is for people with advanced dry age-related macular degeneration (AMD) that has caused geographic atrophy—damage to the central part of the retina. The study aims to see if the treatment is safe and can help slow vision loss.
Edison, New JerseyAges 50–85 - NCT07174687RecruitingPhase 2
SGLT2 inhibitor drug for geographic atrophy in dry AMD
This trial tests whether an SGLT2 inhibitor (a diabetes drug) can help slow geographic atrophy, a type of advanced dry age-related macular degeneration. It might be an option if you have dry AMD with specific types of retinal damage and haven't had other treatments.
St Louis, MissouriAges 50 years+ - NCT07223489Recruiting
Understanding Adult SMA Diagnosis & Treatment Experiences
This trial explores the experiences of adults with spinal muscular atrophy (SMA) in the MedStar Health System, looking at how they are diagnosed and treated, and any differences in care they may face.
Washinton, District of ColumbiaAges 18 years+ - NCT07231549Recruiting
SMA study tracking health over time in Spain
This study collects health information from people with spinal muscular atrophy (SMA) over time to learn more about the disease and how to improve care. It may help researchers understand SMA better.
Esplugues de LlobregatAges Any age - NCT07265232RecruitingPhase 3
Gene therapy for spinal muscular atrophy in low-resource settings
This trial tests a new gene therapy called Vesemnogene Lantuparvovec for people with spinal muscular atrophy (SMA). It is designed for patients in low- and middle-income countries who cannot access or did not respond to other treatments. The goal is to see if the therapy is safe and effective in real-world conditions.
Jakarta, IndonesiaAges 6 months+ - NCT07286565Recruiting
Remote motor development study for early-diagnosed DMD or SMA
This study remotely tracks motor development in children with Duchenne muscular dystrophy or spinal muscular atrophy who were diagnosed at birth or before symptoms started. It aims to see if early monitoring helps improve long-term care and outcomes.
LiègeAges 4 months+ - NCT07332702Recruiting
Spinal muscular atrophy gene study
This study looks at changes in two genes, SMN1 and SMN2, which are linked to spinal muscular atrophy (SMA). It aims to better understand the different versions of these genes in healthy people and those with SMA. Participating involves a blood sample and genetic analysis.
RouenAges 18 years+ - NCT07215234RecruitingPhase 1/Phase 2
Study of an injection for geographic atrophy in AMD
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
Peoria, ArizonaAges 60 years+ - NCT02194816Recruiting
Online survey study for people with Parkinson’s or Parkinsonism
This study looks at how changing certain factors over time relates to symptoms in Parkinson’s disease and related conditions. You may help researchers by completing longer online surveys every 6 months for 5 years.
Kenmore, WashingtonAges 19 years+ - NCT03011541Recruiting
Stem cell treatment for damaged retina or optic nerve
This study looks at stem-cell treatment to help vision in adults whose retina or optic nerve damage is not expected to improve on its own. You may be a candidate if your eye exam shows documented, stable or slowly changing damage and you can safely complete follow-up eye visits.
Westport, ConnecticutAges 18 years+ - NCT07400198Recruiting
Walking and Bone Health Study for SMA
This study looks at walking and bone health in people with spinal muscular atrophy (SMA). It helps researchers understand how SMA affects your gait (the way you walk) and your bones, which could lead to better treatments.
New York, New YorkAges 8–50 - NCT07444476RecruitingPhase 3
Study of salanersen for spinal muscular atrophy (ages 15-60)
This trial tests a medicine called salanersen (BIIB115) to see how well it improves movement and how safe it is in people with spinal muscular atrophy (SMA). It includes those who have never taken an SMA drug or are currently on risdiplam and willing to switch.
Norfolk, VirginiaAges 15–60 - NCT07446894RecruitingPhase 3
Testing MSA-01 for multiple system atrophy
This phase 3 trial tests a new oral drug (MSA-01) for people with multiple system atrophy. It aims to see if the drug can slow disease progression and improve daily function.
Nagoya, Aichi-kenAges 30–79 - NCT07467187Recruiting
Home Ventilation with Tracheostomy in Denmark (2016–2025)
This study looks at people in Denmark who need a home ventilator through a tracheostomy. It aims to understand their care and outcomes over several years.
CopenhagenAges Any age - NCT07478172Recruiting
Electrical muscle stimulation exercise for neuromuscular disease
This study tests whether whole-body electrical muscle stimulation (using small electrodes on the skin) can help adults with certain neuromuscular diseases exercise and improve muscle strength. It may be an option if you can stand for about 15 minutes at a time and have some muscle strength left.
Columbia, MissouriAges 18 years+ - NCT07531927Recruiting
Electrical Stimulation for Geographic Atrophy Vision Loss
This study tests whether gentle electrical stimulation applied to the eye can help slow vision loss from geographic atrophy, a common cause of blindness in older adults. The treatment uses a special device to stimulate the retina (the light-sensing tissue in the back of your eye).
HamburgAges 60 years+ - NCT07543003Recruiting
Wearable Monitoring for Young Children With Spinal Muscular Atrophy
This study uses wearable devices (like smartwatches or activity trackers) to monitor movement and motor development in young children with spinal muscular atrophy (SMA), a rare genetic condition affecting muscle strength. The goal is to see if wearables can track disease progression and treatment response better than traditional clinic visits.
OxfordAges Up to 4 years - NCT07556406Recruiting
Eye imaging study for age-related macular degeneration
This study uses specialized eye imaging to track changes in geographic atrophy, a type of vision loss from macular degeneration. Researchers will use new imaging techniques to better understand how this condition progresses and how treatments work.
San Francisco, CaliforniaAges 55 years+
Hear when a new Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for atrophy?
- Yes. Clin2 currently lists 272 recruiting atrophy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atrophy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atrophy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.